121 related articles for article (PubMed ID: 37418175)
1. Structural dynamics of clinically-reported VUS in the BARD1 ARD-BRCT region to predict the molecular basis of alterations.
Barua SA; Choudhary RK; Gawde J; Mishra N; Varma AK
J Biomol Struct Dyn; 2024 Jul; 42(11):5475-5484. PubMed ID: 37418175
[TBL] [Abstract][Full Text] [Related]
2. Structural basis to stabilize the domain motion of BARD1-ARD BRCT by CstF50.
Choudhary RK; Siddiqui MQ; Thapa PS; Gadewal N; Nachimuthu SK; Varma AK
Sci Rep; 2017 Jun; 7(1):3849. PubMed ID: 28634376
[TBL] [Abstract][Full Text] [Related]
3. The BARD1 C-terminal domain structure and interactions with polyadenylation factor CstF-50.
Edwards RA; Lee MS; Tsutakawa SE; Williams RS; Nazeer I; Kleiman FE; Tainer JA; Glover JN
Biochemistry; 2008 Nov; 47(44):11446-56. PubMed ID: 18842000
[TBL] [Abstract][Full Text] [Related]
4.
Barua SA; Goswami N; Mishra N; Sawant UU; Varma AK
ACS Omega; 2022 Dec; 7(49):44772-44785. PubMed ID: 36530327
[TBL] [Abstract][Full Text] [Related]
5. Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.
Laufer M; Nandula SV; Modi AP; Wang S; Jasin M; Murty VV; Ludwig T; Baer R
J Biol Chem; 2007 Nov; 282(47):34325-33. PubMed ID: 17848578
[TBL] [Abstract][Full Text] [Related]
6. Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor.
Chatterjee P; Karn R; Emerson IA; Banerjee S
Mol Biotechnol; 2024 Apr; 66(4):718-736. PubMed ID: 36732462
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the BARD1 BRCT domains.
Birrane G; Varma AK; Soni A; Ladias JA
Biochemistry; 2007 Jul; 46(26):7706-12. PubMed ID: 17550235
[TBL] [Abstract][Full Text] [Related]
8. Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain.
Yadegari F; Farahmand L; Esmaeili R; Zarinfam S; Majidzadeh-A K
J Biomol Struct Dyn; 2024 Jul; 42(11):5734-5746. PubMed ID: 37948190
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences.
Fox D; Le Trong I; Rajagopal P; Brzovic PS; Stenkamp RE; Klevit RE
J Biol Chem; 2008 Jul; 283(30):21179-86. PubMed ID: 18480049
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics simulations reveal the effect of mutations in the RING domains of BRCA1-BARD1 complex and its relevance to the prognosis of breast cancer.
Kiewhuo K; Priyadarsinee L; Sarma H; Sastry GN
J Biomol Struct Dyn; 2023; 41(22):12734-12752. PubMed ID: 36775657
[TBL] [Abstract][Full Text] [Related]
11. Classification of VUS and unclassified variants in
Sinha S; Wang SM
Comput Struct Biotechnol J; 2020; 18():723-736. PubMed ID: 32257056
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation.
Hu Q; Botuyan MV; Zhao D; Cui G; Mer E; Mer G
Nature; 2021 Aug; 596(7872):438-443. PubMed ID: 34321665
[TBL] [Abstract][Full Text] [Related]
13. Multimodal approach to explore the pathogenicity of BARD1, ARG 658 CYS, and ILE 738 VAL mutants.
Choudhary RK; Vikrant ; Siddiqui QM; Thapa PS; Raikundalia S; Gadewal N; Kumar NS; Hosur MV; Varma AK
J Biomol Struct Dyn; 2016 Jul; 34(7):1533-44. PubMed ID: 26307947
[TBL] [Abstract][Full Text] [Related]
14. Thermal and chemical denaturation of the BRCT functional module of human 53BP1.
Thanassoulas A; Nomikos M; Theodoridou M; Stavros P; Mastellos D; Nounesis G
Int J Biol Macromol; 2011 Oct; 49(3):297-304. PubMed ID: 21600917
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
Sauer MK; Andrulis IL
J Med Genet; 2005 Aug; 42(8):633-8. PubMed ID: 16061562
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity.
Adamovich AI; Banerjee T; Wingo M; Duncan K; Ning J; Martins Rodrigues F; Huang KL; Lee C; Chen F; Ding L; Parvin JD
PLoS Genet; 2019 Mar; 15(3):e1008049. PubMed ID: 30925164
[TBL] [Abstract][Full Text] [Related]
17. Thermodynamic study of the BRCT domain of BARD1 and its interaction with the -pSER-X-X-Phe- motif-containing BRIP1 peptide.
Thanassoulas A; Nomikos M; Theodoridou M; Yannoukakos D; Mastellos D; Nounesis G
Biochim Biophys Acta; 2010 Sep; 1804(9):1908-16. PubMed ID: 20451671
[TBL] [Abstract][Full Text] [Related]
18. Functional Analysis of BARD1 Missense Variants in Homology-Directed Repair of DNA Double Strand Breaks.
Lee C; Banerjee T; Gillespie J; Ceravolo A; Parvinsmith MR; Starita LM; Fields S; Toland AE; Parvin JD
Hum Mutat; 2015 Dec; 36(12):1205-14. PubMed ID: 26350354
[TBL] [Abstract][Full Text] [Related]
19. Identification of functional SNPs in BARD1 gene and in silico analysis of damaging SNPs: based on data procured from dbSNP database.
Alshatwi AA; Hasan TN; Syed NA; Shafi G; Grace BL
PLoS One; 2012; 7(10):e43939. PubMed ID: 23056176
[TBL] [Abstract][Full Text] [Related]
20. Biophysical evaluation to categorize pathogenicity of cancer-predisposing mutations identified in the BARD1 BRCT domain.
Choudhary RK; Siddiqui MQ; Gadewal N; Kumar NS; Kuligina ES; Varma AK
RSC Adv; 2018 Sep; 8(59):34056-34068. PubMed ID: 35548793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
